ARGX
Price
$580.37
Change
+$6.86 (+1.20%)
Updated
Jun 5, 04:59 PM (EDT)
Capitalization
35.63B
56 days until earnings call
BBIO
Price
$37.97
Change
-$0.05 (-0.13%)
Updated
Jun 5, 04:11 PM (EDT)
Capitalization
7.22B
56 days until earnings call
Interact to see
Advertisement

ARGX vs BBIO

Header iconARGX vs BBIO Comparison
Open Charts ARGX vs BBIOBanner chart's image
argenx SE
Price$580.37
Change+$6.86 (+1.20%)
Volume$1.12K
Capitalization35.63B
BridgeBio Pharma
Price$37.97
Change-$0.05 (-0.13%)
Volume$5.25K
Capitalization7.22B
ARGX vs BBIO Comparison Chart
Loading...
ARGX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
BBIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ARGX vs. BBIO commentary
Jun 05, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARGX is a Hold and BBIO is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 05, 2025
Stock price -- (ARGX: $573.51 vs. BBIO: $38.02)
Brand notoriety: ARGX and BBIO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARGX: 51% vs. BBIO: 116%
Market capitalization -- ARGX: $35.63B vs. BBIO: $7.22B
ARGX [@Biotechnology] is valued at $35.63B. BBIO’s [@Biotechnology] market capitalization is $7.22B. The market cap for tickers in the [@Biotechnology] industry ranges from $318.09B to $0. The average market capitalization across the [@Biotechnology] industry is $2.31B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARGX’s FA Score shows that 1 FA rating(s) are green whileBBIO’s FA Score has 1 green FA rating(s).

  • ARGX’s FA Score: 1 green, 4 red.
  • BBIO’s FA Score: 1 green, 4 red.
According to our system of comparison, BBIO is a better buy in the long-term than ARGX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARGX’s TA Score shows that 4 TA indicator(s) are bullish while BBIO’s TA Score has 4 bullish TA indicator(s).

  • ARGX’s TA Score: 4 bullish, 7 bearish.
  • BBIO’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, both ARGX and BBIO are a bad buy in the short-term.

Price Growth

ARGX (@Biotechnology) experienced а -1.08% price change this week, while BBIO (@Biotechnology) price change was +17.85% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.11%. For the same industry, the average monthly price growth was +9.95%, and the average quarterly price growth was -2.16%.

Reported Earning Dates

ARGX is expected to report earnings on Jul 31, 2025.

BBIO is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+4.11% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ARGX($35.6B) has a higher market cap than BBIO($7.22B). BBIO YTD gains are higher at: 38.557 vs. ARGX (-6.747). ARGX has higher annual earnings (EBITDA): 365M vs. BBIO (-551.92M). ARGX has more cash in the bank: 3.1B vs. BBIO (541M). ARGX has less debt than BBIO: ARGX (34M) vs BBIO (1.86B). ARGX has higher revenues than BBIO: ARGX (2.58B) vs BBIO (127M).
ARGXBBIOARGX / BBIO
Capitalization35.6B7.22B493%
EBITDA365M-551.92M-66%
Gain YTD-6.74738.557-17%
P/E Ratio34.97N/A-
Revenue2.58B127M2,031%
Total Cash3.1B541M573%
Total Debt34M1.86B2%
FUNDAMENTALS RATINGS
ARGX vs BBIO: Fundamental Ratings
ARGX
BBIO
OUTLOOK RATING
1..100
69
VALUATION
overvalued / fair valued / undervalued
1..100
74
Overvalued
4
Undervalued
PROFIT vs RISK RATING
1..100
1891
SMR RATING
1..100
9197
PRICE GROWTH RATING
1..100
5844
P/E GROWTH RATING
1..100
84100
SEASONALITY SCORE
1..100
751

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BBIO's Valuation (4) in the null industry is significantly better than the same rating for ARGX (74) in the Pharmaceuticals Other industry. This means that BBIO’s stock grew significantly faster than ARGX’s over the last 12 months.

ARGX's Profit vs Risk Rating (18) in the Pharmaceuticals Other industry is significantly better than the same rating for BBIO (91) in the null industry. This means that ARGX’s stock grew significantly faster than BBIO’s over the last 12 months.

ARGX's SMR Rating (91) in the Pharmaceuticals Other industry is in the same range as BBIO (97) in the null industry. This means that ARGX’s stock grew similarly to BBIO’s over the last 12 months.

BBIO's Price Growth Rating (44) in the null industry is in the same range as ARGX (58) in the Pharmaceuticals Other industry. This means that BBIO’s stock grew similarly to ARGX’s over the last 12 months.

ARGX's P/E Growth Rating (84) in the Pharmaceuticals Other industry is in the same range as BBIO (100) in the null industry. This means that ARGX’s stock grew similarly to BBIO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARGXBBIO
RSI
ODDS (%)
Bearish Trend 2 days ago
46%
Bearish Trend 2 days ago
74%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
60%
Bearish Trend 2 days ago
77%
Momentum
ODDS (%)
Bearish Trend 2 days ago
58%
Bullish Trend 2 days ago
77%
MACD
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
77%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
63%
Bullish Trend 2 days ago
77%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
66%
Bearish Trend 2 days ago
84%
Advances
ODDS (%)
Bullish Trend 16 days ago
71%
Bullish Trend 2 days ago
78%
Declines
ODDS (%)
Bearish Trend 2 days ago
63%
Bearish Trend 9 days ago
84%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
68%
Aroon
ODDS (%)
Bullish Trend 2 days ago
78%
Bearish Trend 2 days ago
74%
View a ticker or compare two or three
Interact to see
Advertisement
ARGX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
BBIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
BBIN67.410.36
+0.54%
JPMorgan BetaBuilders Intl Eq ETF
KWT37.570.10
+0.26%
iShares® MSCI Kuwait ETF
NAPR50.190.09
+0.19%
Innovator Nasdaq-100 Pwr Bffr ETF Apr
BCDF30.08-0.01
-0.04%
Horizon Kinetics Blockchain Dev ETF
CDC62.69-0.46
-0.73%
VictoryShares US EQ Inc Enh Vol Wtd ETF

BBIO and

Correlation & Price change

A.I.dvisor indicates that over the last year, BBIO has been loosely correlated with ARGX. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if BBIO jumps, then ARGX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BBIO
1D Price
Change %
BBIO100%
+1.33%
ARGX - BBIO
46%
Loosely correlated
-0.54%
AXON - BBIO
44%
Loosely correlated
+2.76%
ARRY - BBIO
43%
Loosely correlated
-0.43%
PMN - BBIO
43%
Loosely correlated
+2.81%
ROIV - BBIO
42%
Loosely correlated
-0.31%
More